Drug Discovery
With our chemistry SDL "ChemASAP" and the "Molecule Archive" we will accelerate experimental screening cycles by utilizing automated chemical synthesis workflows
ChemASAP
The aim of the Chem.ASAP (Automated Synthesis and Analysis Platform for Chemistry) SDL is to build a platform for fully automated and autonomous chemical reaction processes for the production and repurposing of therapeutics and theranostics controlled by intelligent process control (AI) and analysis. The small molecules designed and produced by ChemASAP can also be used to produce polymers for biomedical applications. Advanced tools for miniaturization and parallelization of chemical reactions will be developed and integrated to accelerate experiments by a factor of 100 compared to manual synthesis. The project benefits from a digital infrastructure built over many years to generate and reuse machine-readable processes and data.
The SDL Chem.ASAP has been under construction since 2021 and is the most advanced in this SDL alliance with an investment of >€4 million.
Autonomous DMTA Cycles
Early-stage drug discovery for small molecules and biomaterials building blocks is guided by the Design-Make-Test-Analyze (DMTA) cycle. The DMTA is a hypothesis-driven framework aimed at optimizing the design and performance of compounds or materials. The process involves designing a compound, synthesizing it, testing its properties, and analyzing the results. Each stage of the cycle yields valuable high quality data, which will be used in several cycles by machine learning tools to achieve a significant benefit for the compound function.
ChemASAP
With our chemistry SDL we will accelerate experimental screening cycles by utilizing automated chemical synthesis workflows
link
Molecule Archive